Aussie team advises on major anti-cancer drug royalty deal
A team from Norton Rose Fulbright
has acted as the Australian advisers on the partial monetisation of a royalty due for sales of venetoclax, a new anti-cancer drug.
The firm has been involved in the project with the Walter and Eliza Institute of Medical Research for more than a decade and the $325 million deal is a milestone for the institute which will enhance its global reputation in the medical research field.
“This transaction is a landmark deal for Australia and may be transformational for others in terms of commercialisation. It has been tremendously rewarding to work with the Walter and Eliza Hall Institute for more than a decade and we are proud to have played a role in helping the Institute further this important work in finding new treatments for cancer,” said Melbourne partner Bernard O’Shea, who led the team and is co-head of Norton’s Australia life sciences and healthcare industry team.
O’Shea was assisted mainly by associate Rohan Sridhar.
MinterEllison hires property expert from international firm
MinterEllison has hired property development expert Carla Deluca as a partner in its Melbourne office.
Her practice spans real estate matters across a broad range of industries and sectors. She is the Australian firm’s second lateral hire from Herbert Smith Freehills
following that of class actions specialist David Taylor, who joined the Sydney office last month.
MinterEllison’s Infrastructure, Construction & Property team now has 36 partners across the country.
Dentons expands Singapore energy practice
Dentons Rodyk & Davidson in Singapore has expanded its energy, infrastructure and project finance group with a hire from Ashurst
Kunal Kapoor has joined as a partner, adding his experience of project development work, project finance, private M&A, commodity offtakes and trading, and structured finance in the energy sector.
His appointment brings the firm’s energy practice group in the city state to 17.